Eicosanoid Inflammatory Mediators Are Robustly Associated with Blood Pressure in the General Population

Joonatan Palmu MD[1,2], Jeramie D. Watrous PhD[3], Kysha Mercader BSc[3], Aki S. Havulinna DSc[2,4], Kim A. Lagerborg BSc[3], Aaro Salosensaari MSc[5], Mike Inouye PhD[6,7], Martin G. Larson SD[7,8], Jian Rong PhD[7], Ramachandran S. Vasan[7,9], Leo Lahti PhD[5], Allen Andres PhD[3], Susan Cheng MD[7,10,11], Pekka Jousilahti[2], Veikko Salomaa MD[2], Mohit Jain MD[3]*, Teemu J. Niiranen MD[1,2,12]*

*Equal contribution

[1]Department of Internal Medicine, University of Turku, Finland

[2]Department of Public Health Solutions, Finnish Institute for Health and Welfare, Finland

[3]Departments of Medicine and Pharmacology, University of California San Diego, CA

[4]Institute for Molecular Medicine Finland, FIMM-HiLIFE, Finland

[5]Department of Future Technologies, University of Turku, Finland

[6]Department of Public Health and Primary Care, University of Cambridge, United Kingdom

[7]National Heart, Lung and Blood Institute's and Boston University's Framingham Heart Study, Framingham, MA

[8]Department of Biostatistics, Boston University School of Public Health, Boston, MA

[9]Sections of Preventive medicine and Epidemiology, and Cardiovacsular Medicine, Department of Medicine; Department of Epidemiology; Boston University Schools of Medicine and Public Health, Boston, MA

[10]Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA

[11]Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA

[12]Division of Medicine, Turku University Hospital, Finland

Short title: **Eicosanoid Inflammatory Mediators and Hypertension**

Total word count of manuscript: 5484

Word count of the abstract: 249

Total number of figures: 5

Corresponding Author: Joonatan Palmu, Department of Internal Medicine, University of Turku, Finland, E-mail: jjmpal@utu.fi; Tel: +358 2 313 0000; Fax: +358 2 313 8436

Abstract

Epidemiological and animal studies have associated systemic inflammation with blood pressure (BP). However, the mechanistic factors linking inflammation and BP remain unknown. Fatty acid derived eicosanoids serve as mediators of inflammation and have been suggested to also regulate renal vascular tone, peripheral resistance, renin-angiotensin system, and endothelial function. We therefore hypothesize that specific pro- and anti-inflammatory eicosanoids are linked with BP. We studied a population sample of 8099 FINRISK 2002 participants randomly drawn from the Finnish population register (53% women, mean age 48±13 years) and, for external validation, a sample of 2859 Framingham Heart Study (FHS) Offspring study participants (55% women, mean age 66±9 years). Using non-targeted liquid chromatography-mass spectrometry, we profiled 545 distinct high-quality eicosanoids and related oxylipin mediators in plasma. Adjusting for conventional hypertension risk factors, we observed 187 (34%) metabolites that were significantly associated with systolic BP (P < Bonferroni-corrected threshold of 0.05/545). We used forward selection linear regression modeling in FINRISK to define a general formula for individual eicosanoid risk score. Individuals of the top risk score quartile in FINRISK had a 9.0 mmHg (95% CI 8.0-10.1) higher systolic BP compared with individuals in the lowest quartile in fully adjusted models. Observed metabolite associations were consistent across FINRISK and FHS. In conclusion, plasma eicosanoids demonstrate strong associations with BP in the general population. As eicosanoid compounds affect numerous physiological processes that are central to

BP regulation, they may offer new insights regarding pathogenesis of hypertension, as well as serve as potential targets for therapeutic intervention.

Keywords: blood pressure, eicosanoids, hypertension, liquid chromatography–mass spectrometry, metabolite

Introduction

A vast majority of hypertensive patients (>95%) are classified as having primary (essential) hypertension, a heterogeneous condition of hypertension that has no identifiable cause (by definition). Essential hypertension is most likely the consequence of an interaction between genetic factors and environmental factors (e.g., obesity, insulin resistance, sedentary lifestyle, stress, and sodium intake).[1] Intriguingly, all of the aforementioned factors are also related to chronic low-grade inflammation, underscoring the need to further investigate inflammation as a potential mainstay pathologic mechanism underlying hypertension.[2]

The upstream initiation of inflammatory activity in humans is governed mainly by substrates and products of polyunsaturated fatty acids.[3] Termed eicosanoids, the small molecule derivatives of arachidonic acid and other polyunsaturated fatty acids serve as both activators and suppressors of systemic inflammatory activity.[3] Data derived mainly from animal studies suggest that eicosanoid compounds affect renal vascular tone, urine sodium excretion, peripheral resistance, kidney disease, renin-angiotensin-aldosterone system, and endothelial function – factors that are central to blood pressure (BP) regulation itself.[4–9] Published data have also demonstrated that a few, select eicosanoids, such as 20-hydroxyeicosatetraenoic acid (20-HETE), and genetic polymorphisms that regulate the levels of these eicosanoids, are altered in small samples of individuals and animals with hypertension.[10–12]

Until recently, sensitive methods for detecting and quantifying eicosanoids in large

sample sizes were lacking. However, mass spectrometry (MS) based analytics now allow for the rapid large-scale quantification of several hundred upstream eicosanoids in human plasma.[13,14] Our goal was to gain a more detailed understanding of how upstream inflammatory mediators are related to an individual's prevalence for hypertension. We quantified a comprehensive panel of >500 distinct high-quality upstream eicosanoids and related oxylipin mediators in FINRISK 2002 (N=8099) and Framingham Heart Study Offspring (FHS Offspring; N=2859) cohort participants using liquid chromatography-MS (LC-MS) and related these eicosanoids and eicosanoid profiles to BP traits.

Methods

Cohorts

The FINRISK 2002 study used a random population sample of individuals aged 25–74 years from six geographical areas of Finland. The sampling was stratified by sex, region and 10-year age group for a population sample of 13500 individuals; the overall participation rate was 65.2% (N=8798). The sampling has been previously described in detail.[15] Plasma LC-MS was performed successfully on N=8292 participants. After excluding 193 participants with missing covariate data, N=8099 individuals were included in the analyses as the discovery cohort for the present investigation.

The first-generation (i.e. the 'Original') cohort of the FHS included a random sample of two thirds of the adult population of Framingham, MA who were enrolled in a longitudinal community-based cohort study in 1948. The FHS Offspring includes 5124 participants – children of the first-generation cohort and their spouses, who have been re-examined every four-to-eight years since the first examination in 1971. The characteristics and study protocol of FHS Offspring cohort have been published.[16] For this study, we considered N=3002 individuals who participated in the eight examination cycle of FHS Offspring in 2005–2008 and had assays for eicosanoids with LC-MS. After excluding 143 participants with missing covariates, we included N=2859 participants as the replication cohort.

Ethical Approval

The FINRISK 2002 study was approved by Coordinating Ethics Committee of the Helsinki University Hospital District. FHS Offspring was approved by Boston University Medical Center's Institutional Review Board. All participants in both studies provided written informed consent. Participants' consent to publication of information was not required because the participants remain unidentifiable.

Clinical Evaluation and Definitions

Participants of both cohorts provided a medical history, including information on medication use, and underwent a physical examination and laboratory assessment of cardiovascular risk factors at baseline. The methodologies of these examinations have been described previously in detail.[15,16] At all examinations, a healthcare professional performed two (FHS Offspring) or three (FINRISK) sequential BP measurements using a mercury column sphygmomanometer on seated participants according to a standardized protocol. We defined the BP at a given examination as the mean of all sequentially measured BP values. We defined hypertension as BP ≥140/90 mmHg or use of antihypertensive medication. Antihypertensive medication use was based on self-report in both studies. We defined pulse pressure as systolic minus diastolic BP and mean arterial pressure as [(2 x diastolic BP) + systolic BP] / 3. We defined body mass index as weight (kg) divided by height (m) squared and current smoking as self-reported daily used of tobacco products. In FINRISK 2002, prevalent diabetes was defined as self-reported diabetes, a previous diagnostic code indicating diabetes in the nationwide Care Register for Health Care (International Statistical Classification of Diseases and Related Health Problems[17] (ICD) version

10 codes E10-E14, ICD-9 code 250, or ICD-8 code 250), a previous diabetes medication purchase (ATC code A10*) in the nationwide Prescribed Drug Purchase register, or a diabetes medication code in the nationwide Reimbursed Medication Register. In FHS Offspring, prevalent diabetes was defined as a fasting plasma glucose ≥7.0 mmol/l or self-reported use of glucose-lowering medications.

Eicosanoid profiling

Using a directed non-targeted LC-MS approach in conjunction with computational chemical networking of spectral fragmentation patterns, we identified 545 eicosanoids and related oxylipins in the FINRISK. The methods of plasma eicosanoid profiling using LC-MS have been previously described in detail.[13,14] Metabolite data were adjusted for technical variation in off-plate pooled plasma samples and in spike-in internal standards. Missing values were replaced with minimum value for each eicosanoid abundance. The six eicosanoids and related oxylipin mediators included in the risk score were matched between FINRISK and FHS by comparing their LC-MS profiles. These metabolites were also identified, if possible, through comparisons with reference standards and online databases.

Statistical analyses

We normalized eicosanoid abundances using median absolute deviation; we calculated the median of the absolute difference from the median, and used this value to scale all analyte values for a given assay plate. We used linear and logistic regression models to examine the associations between each eicosanoid molecule and BP traits (systolic BP, diastolic BP, pulse pressure, mean arterial pressure, and

hypertension). We adjusted for multiple comparisons using Bonferroni correction to minimize the probability of type I error.[18] Relations between eicosanoids significantly associated with systolic blood arterial pressure were assessed using Spearman correlation and ordered using hierarchical cluster analysis with complete linkage method. We assessed the multivariable association between eicosanoids significantly related to systolic BP using stepwise linear regression modeling with forward selection and a Bonferroni-corrected inclusion threshold of p=0.05/545. For the six eicosanoids that remained in the models, we calculated eicosanoid risk scores according to the formula $\beta_1X_1 + \beta_2X_2 + ... + \beta_nX_n$, with X_n denoting the standardized value for the nth eicosanoid abundance, and β_n denoting the regression coefficient from the regression model for systolic BP containing the statistically significant eicosanoids.[19] We assessed the odds of hypertension and increase in systolic BP by 1-SD increases and by quartiles of the risk scores using unadjusted and multivariable adjusted logistic and linear regression models. We replicated these analyses in FHS Offspring using the eicosanoid abundances in FHS and the regression coefficients from FINRISK. We adjusted all analyses for age, sex, BMI, current smoking, diabetes, antihypertensive medication, and mass spectrometry batch. We used R version 3.6.1[20] for all analyses. The source code for the analyses is openly available at doi:10.5281/zenodo.3604123.[21]

Results

The characteristics of FINRISK (N=8099, mean age 48.0±13.1 years, 53.1% female) and FHS (N=2859, mean age 66.3±8.9 years, 54.7% women) cohorts are shown in **Table 1**.

Association between Eicosanoids and BP Traits

Of the eicosanoids and related oxylipin mediators, 187 (34.3%) were significantly associated with systolic BP, 124 (22.8%) with diastolic BP, 177 (32.5%) with mean arterial pressure, 161 (29.5%) with pulse pressure, and 155 (28.4%) with hypertension in FINRISK (**Figure 1, Table S1**). We selected systolic BP as our main outcome variable due to its strong association with cardiovascular diseases. We observed 175 (93.6%) positive and 12 (6.4%) negative associations for systolic BP (**Figure 1, Table S1**). The heatmaps of pairwise correlations for the 187 metabolites related to systolic BP are shown in **Figure 2** and **Figure S1**. This analysis revealed strong overall correlations, but only minor clustering of the eicosanoids.

Independent Determinants of BP and Hypertension

We used forward selection linear regression modeling with a Bonferroni-corrected inclusion threshold to define a set of metabolites that was independently associated with systolic BP. In FINRISK, these six metabolites were 11-dehydro-2,3-dinor thromboxane B_2 (TXB_2), 12-hydroxyheptadecatrienoic acid (12-HHTrE), 265.1809/3.57 (putative eicosanoid), 295.2279/4.89 (putative eicosanoid), 319.2280/5.67 (unknown), and adrenic acid (**Table S2)**. Two of these six metabolites

could not be detected in FHS plasma samples (11-dehydro-2,3-dinor-TXB_2 and 295.2279/4.89). Comparing single metabolite associations, adjusted for relevant covariates, demonstrated that effect sizes between the metabolites were highly consistent across the two cohorts (**Figure 3, Table S3**).

Eicosanoid risk score

We defined an eicosanoid risk score using the effect sizes in FINRISK for the six previously mentioned metabolites (**Table S2**). The abundances of the two non-detected metabolites in FHS were treated as zero values. Individuals in the top risk quartile had 9.0 mmHg (95% CI 8.0-10.1 mmHg) higher systolic BP in FINRISK and 6.8 mmHg (95% CI 5.1-8.5 mmHg) in FHS compared with individuals in the lowest quartile (**Figure 4**, **Figure 5, Table S4, Table S5)**. The odds for hypertension were respectively 2.3 (95% CI 2.0–2.6) and 2.0 (95% CI 1.6-2.5) for the top quartile compared to the lowest quartile (**Figure 4**, **Figure 5)**. These associations were consistent across FINRISK and FHS.

Discussion

Using a directed non-targeted LC-MS approach in well-phenotyped, large community-based cohorts, we identified 187 eicosanoids and related oxylipins that were associated with systolic BP. FINRISK 2002 participants in the top quartile of the eicosanoid risk score had 9.0 mmHg greater systolic BP and a >2-fold odds of hypertension, compared with individuals in the lowest quartile. These findings were replicated in the FHS Offspring participants.

The upstream initiation of inflammatory activity in humans is governed mainly by substrates and products of polyunsaturated ω-3 and ω-6 20-carbon fatty acids.[7,22] The small molecule derivatives of arachidonic acid and other polyunsaturated fatty acids, termed eicosanoids, serve as both activators and suppressors of systemic inflammatory activity.[23,24] The majority of research on systemic inflammation in humans has focused on downstream markers of inflammatory activity such as cytokines and acute phase reactants. Recent work by us and others has shown that chronic elevation in these downstream markers is associated with a variety of cardiovascular disease risk traits and outcomes.[25,26] In particular, several cross-sectional and prospective studies in humans have found an association of plasma concentrations of downstream low-grade inflammation markers, such as interleukin-6, intercellular adhesion molecule-1, C-reactive protein, and tumor necrosis factor alpha, with arterial stiffness and hypertension.[27–33]. Although downstream markers of inflammation are associated with hypertension and a variety of cardiovascular disease outcomes, evidence for a clinically important, causal role of these

biomarkers has been mixed.[34] In addition, despite inflammation being pivotal in the development of atherosclerosis and certain medications with anti-inflammatory properties clearly reduce cardiovascular disease risk, the extent to which any given inflammatory pathway warrants attention as a direct putative target for therapy is unknown.[35] Such results have now led experts to suggest that, where inflammation is concerned, causal factors may be upstream.[34]

This study is the first to comprehensively examine the association between eicosanoids and BP in humans. Prior studies with study samples consisting of tens of hypertensive subjects with a panel of a few, mainly cytochrome P450 pathway eicosanoids have demonstrated that eicosanoids, in general, affect regulation of renal function, vascular tone, and the development of hypertension.[12,36–39] Our results from a large, population-based sample demonstrate that a large number of eicosanoid species are related to BP in both a positive and negative way. In addition, we demonstrate that a distinct eicosanoid score is related to a >2-fold odds of hypertension.

Eicosanoids are metabolized via three general pathways that involve that involve cytochrome P450 monooxygenases, cyclooxygenases, and lipooxygenases. Several of the identified metabolites that remained in the six-eicosanoid risk score are members of these pathways. The cytochrome P450 pathway metabolizes arachidonic acid to several eicosanoids, including 20-HETE and EETs.[8] These metabolites are critical in BP regulation and also provide cardio- and renoprotective effects in chronic kidney disease.[8] Cyclooxygenase-derived prostanoids, which

include 11-dehydro-2,3-dinor-TXB_2 identified in our study, modulate renal vasodilatation, natriuretic mediator excretion, and BP during high salt diet.[40–42] 11-dehydro-2,3-dinor-TXB_2, has also been associated in clinical studies with thrombogenesis, pregnancy-induced hypertension, and cardiovascular events.[43–45] Another metabolite that was included in our six-eicosanoid risk score, 12-HHTrE, a product of arachidonic acid metabolism through the 5-lipoxygenase pathway and nonenzymatic degradation product of prostanoids thromboxane A2 and prostaglandin H2, has vasoconstrictor effects.[46,47] In addition to eicosanoid pathway products, adrenic acid was also included in our risk score. Adrenic acid is a polyunsaturated 22-carbon fatty acid and mainly a substrate for eicosanoid production.[48] Given the findings from our study and from previous experimental trials, these results provide a strong biological basis for how eicosanoids could affect human BP regulation through several different mechanisms.

Our study has several strengths, such as unselected population sample, external replication of our results, and assays of a large number of eicosanoids. However, our results must be interpreted in the context of potential limitations. First, LC-MS is a highly sensitive method for assessing circulating metabolites. Particularly, of the six metabolites that remained in the final forward-selection regression model in FINRISK, only four were observed in FHS samples. This could in part be explained by the between-cohort age and smoking disparities. Second, the unambiguous metabolite classification and identification is still a challenge in high-throughput LC-MS. However, we have previously demonstrated that these signals are highly consistent with known and putative eicosanoids and related oxylipins in human

plasma.[14] Finally, due to the cross-sectional and observational nature of our study, no causal inferences can be made.

Perspectives

Plasma eicosanoids demonstrate strong associations with BP in the general population and differences between eicosanoid profiles are observed between normotensive versus hypertensive participants. Intriguingly, although most of the associations were positive (harmful species), we observed protective molecules as well. Thus, eicosanoids may offer new insights regarding pathogenesis of hypertension and related adverse outcomes, as well as serve as potential targets for therapeutic intervention.

Acknowledgments

We thank the participants and staff of the FINRISK 2002 and FHS.

Sources of Funding

This work was supported by the Emil Aaltonen Foundation (TN), the Paavo Nurmi Foundation (TN), the Finnish Medical Foundation (TN), the Finnish Foundation for Cardiovascular Research (VS), the Academy of Finland (grant n:o 321351 to TN; 295741, 307127 to LL, 321356 to ASH), Ellison Foundation (SC) and the National Heart, Lung and Blood Institute's Framingham Heart Study (contracts N01HC25195, HHSN268201500001I, and 75N92019D00031), and the following National Institutes of Health grants: R01HL093328 (RSV), R01HL107385 (RSV), R01HL126136 (RSV), R00HL107642 (SC), R01HL131532 (SC), R01HL134168 (SC, MJ), R01HL143227 (SC, MJ), R01ES027595 (MJ, SC), and K01DK116917 (JDW). Dr. Vasan is supported in part by the Evans Medical Foundation and the Jay and Louis Coffman Endowment from the Department of Medicine, Boston University School of Medicine. The funders play no role in the design of the study; the collection, analysis, and interpretation of the data; and the decision to approve publication of the finished manuscript. All authors had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.

Disclosures

VS has received honoraria from Novo Nordisk and Sanofi for consultations and travel support from Novo Nordisk. He also has ongoing research collaboration with

Bayer Ltd. (All unrelated to the present study)

References

1. Carretero Oscar A., Oparil Suzanne. Essential Hypertension. *Circulation*. 2000;101:329–335.

2. Cavalcante JL, Lima JAC, Redheuil A, Al-Mallah MH. Aortic Stiffness: Current Understanding and Future Directions. *J Am Coll Cardiol*. 2011;57:1511–1522.

3. Harizi H, Corcuff J-B, Gualde N. Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology. *Trends Mol Med*. 2008;14:461–469.

4. Fan F, Muroya Y, Roman RJ. Cytochrome P450 eicosanoids in hypertension and renal disease. *Curr Opin Nephrol Hypertens*. 2015;24:37–46.

5. Nasjletti Alberto. The Role of Eicosanoids in Angiotensin-Dependent Hypertension. *Hypertension*. 1998;31:194–200.

6. Capdevila J, Wang W. Role of cytochrome P450 epoxygenase in regulating renal membrane transport and hypertension. *Curr Opin Nephrol Hypertens*. 2013;22:163–169.

7. Mitchell JA, Kirkby NS. Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system. *Br J Pharmacol*. 2019;176:1038–1050.

8. Roman RJ, Fan F. 20-HETE: Hypertension and Beyond. *Hypertens Dallas Tex 1979*. 2018;72:12–18.

9. Imig JD. Epoxyeicosatrienoic Acids, Hypertension, and Kidney Injury. *Hypertension*. 2015;65:476–482.

10. Sun D, Cuevas AJ, Gotlinger K, Hwang SH, Hammock BD, Schwartzman ML, Huang A. Soluble epoxide hydrolase-dependent regulation of myogenic response and blood pressure. *Am J Physiol Heart Circ Physiol*. 2014;306:H1146-1153.

11. Kujal P, Chábová VČ, Škaroupková P, Husková Z, Vernerová Z, Kramer HJ, Walkowska A, Kompanowska-Jezierska E, Sadowski J, Kitada K, Nishiyama A, Hwang SH, Hammock BD, Imig JD, Červenka L. Inhibition of soluble epoxide hydrolase is renoprotective in 5/6 nephrectomized Ren-2 transgenic hypertensive rats. *Clin Exp Pharmacol Physiol*. 2014;41:227–237.

12. Ward NC, Tsai I-J, Barden A, van Bockxmeer FM, Puddey IB, Hodgson JM, Croft KD. A single nucleotide polymorphism in the CYP4F2 but not CYP4A11 gene is associated with increased 20-HETE excretion and blood pressure. *Hypertens Dallas Tex 1979*. 2008;51:1393–1398.

13. Lagerborg KA, Watrous JD, Cheng S, Jain M. High-Throughput Measure of Bioactive Lipids Using Non-targeted Mass Spectrometry. *Methods Mol Biol Clifton NJ*. 2019;1862:17–35.

14. Watrous JD, Niiranen TJ, Lagerborg KA, Henglin M, Xu Y-J, Rong J, Sharma S, Vasan RS, Larson MG, Armando A, Mora S, Quehenberger O, Dennis EA, Cheng S, Jain M. Directed Non-targeted Mass Spectrometry and Chemical Networking for Discovery of Eicosanoids and Related Oxylipins. *Cell Chem Biol*. 2019;26:433-442.e4.

15. Borodulin K, Tolonen H, Jousilahti P, Jula A, Juolevi A, Koskinen S, Kuulasmaa K, Laatikainen T, Männistö S, Peltonen M, Perola M, Puska P, Salomaa V,

Sundvall J, Virtanen SM, Vartiainen E. Cohort Profile: The National FINRISK Study. *Int J Epidemiol*. 2017. doi:10.1093/ije/dyx239.

16. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham offspring study. *Am J Epidemiol*. 1979;110:281–290.

17. International Statistical Classification of Diseases version 10 (in Finnish). Terveyden ja hyvinvoinnin laitos (THL); 2011. Available at http://www.julkari.fi/handle/10024/80324. Accessed October 16, 2019.

18. Etymologia: Bonferroni Correction - Volume 21, Number 2—February 2015 - Emerging Infectious Diseases journal - CDC. doi:10.3201/eid2102.et2102.

19. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS, Jacques PF, Fernandez C, O'Donnell CJ, Carr SA, Mootha VK, Florez JC, Souza A, Melander O, Clish CB, Gerszten RE. Metabolite profiles and the risk of developing diabetes. *Nat Med*. 2011;17:448–453.

20. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2017. Available at https://www.R-project.org/.

21. Palmu J, Lahti L, Niiranen T. eicosanoidsbp: v1.0. 2020. doi:10.5281/zenodo.3604123.

22. Khanapure SP, Garvey DS, Janero DR, Letts LG. Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers. *Curr Top Med Chem*. 2007;7:311–340.

23. Elshenawy O, Shoieb S, Mohamed A, El-Kadi A. Clinical Implications of 20-Hydroxyeicosatetraenoic Acid in the Kidney, Liver, Lung and Brain: An Emerging Therapeutic Target. *Pharmaceutics*. 2017;9:9.

24. Roman RJ. P-450 Metabolites of Arachidonic Acid in the Control of Cardiovascular Function. *Physiol Rev*. 2002;82:131–185.

25. Tuomisto K, Jousilahti P, Sundvall J, Pajunen P, Salomaa V. C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality. A population-based, prospective study. *Thromb Haemost*. 2006;95:511–518.

26. IL6R Genetics Consortium Emerging Risk Factors Collaboration, Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, Gorman DN, Gao P, Saleheen D, Rendon A, Nelson CP, Braund PS, Hall AS, Chasman DI, Tybjærg-Hansen A, Chambers JC, Benjamin EJ, Franks PW, Clarke R, Wilde AAM, Trip MD, Steri M, Witteman JCM, Qi L, van der Schoot CE, de Faire U, Erdmann J, Stringham HM, Koenig W, Rader DJ, Melzer D, Reich D, Psaty BM, Kleber ME, Panagiotakos DB, Willeit J, Wennberg P, Woodward M, Adamovic S, Rimm EB, Meade TW, Gillum RF, Shaffer JA, Hofman A, Onat A, Sundström J, Wassertheil-Smoller S, Mellström D, Gallacher J, Cushman M, Tracy RP, Kauhanen J, Karlsson M, Salonen JT, Wilhelmsen L, Amouyel P, Cantin B, Best LG, Ben-Shlomo Y,

Manson JE, Davey-Smith G, de Bakker PIW, O'Donnell CJ, Wilson JF, Wilson AG, Assimes TL, Jansson J-O, Ohlsson C, Tivesten Å, Ljunggren Ö, Reilly MP, Hamsten A, Ingelsson E, Cambien F, Hung J, Thomas GN, Boehnke M, Schunkert H, Asselbergs FW, Kastelein JJP, Gudnason V, Salomaa V, Harris TB, Kooner JS, Allin KH, Nordestgaard BG, Hopewell JC, Goodall AH, Ridker PM, Hólm H, Watkins H, Ouwehand WH, Samani NJ, Kaptoge S, Di Angelantonio E, Harari O, Danesh J. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. *Lancet Lond Engl*. 2012;379:1205–1213.

27. Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy men. *Hypertens Dallas Tex 1979*. 2001;38:399–403.

28. Lakoski SG, Cushman M, Palmas W, Blumenthal R, D'Agostino RB, Herrington DM. The relationship between blood pressure and C-reactive protein in the Multi-Ethnic Study of Atherosclerosis (MESA). *J Am Coll Cardiol*. 2005;46:1869–1874.

29. Mahmud A, Feely J. Arterial stiffness is related to systemic inflammation in essential hypertension. *Hypertens Dallas Tex 1979*. 2005;46:1118–1122.

30. Sesso HD, Jiménez MC, Wang L, Ridker PM, Buring JE, Gaziano JM. Plasma Inflammatory Markers and the Risk of Developing Hypertension in Men. *J Am Heart Assoc*. 2015;4:e001802.

31. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. *JAMA*. 2003;290:2945–2951.

32. McEniery CM, Spratt M, Munnery M, Yarnell J, Lowe GD, Rumley A, Gallacher J, Ben-Shlomo Y, Cockcroft JR, Wilkinson IB. An analysis of prospective risk factors for aortic stiffness in men: 20-year follow-up from the Caerphilly prospective study. *Hypertens Dallas Tex 1979*. 2010;56:36–43.

33. Chuang S-Y, Hsu P-F, Chang H-Y, Bai C-H, Yeh W-T, Pan H-W. C-reactive protein predicts systolic blood pressure and pulse pressure but not diastolic blood pressure: the Cardiovascular Disease Risk Factors Two-Township Study. *Am J Hypertens*. 2013;26:657–664.

34. Brunner EJ, Kivimäki M, Witte DR, Lawlor DA, Davey Smith G, Cooper JA, Miller M, Lowe GDO, Rumley A, Casas JP, Shah T, Humphries SE, Hingorani AD, Marmot MG, Timpson NJ, Kumari M. Inflammation, insulin resistance, and diabetes--Mendelian randomization using CRP haplotypes points upstream. *PLoS Med*. 2008;5:e155.

35. Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ, CANTOS Trial Group. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. *Lancet Lond Engl*. 2018;391:319–328.

36. Laffer CL, Laniado-Schwartzman M, Wang M-H, Nasjletti A, Elijovich F. Differential regulation of natriuresis by 20-hydroxyeicosatetraenoic Acid in human salt-sensitive versus salt-resistant hypertension. *Circulation*. 2003;107:574–578.

37. Ward NC, Puddey IB, Hodgson JM, Beilin LJ, Croft KD. Urinary 20-hydroxyeicosatetraenoic acid excretion is associated with oxidative stress in hypertensive subjects. *Free Radic Biol Med*. 2005;38:1032–1036.

38. Taddei S, Versari D, Cipriano A, Ghiadoni L, Galetta F, Franzoni F, Magagna A, Virdis A, Salvetti A. Identification of a cytochrome P450 2C9-derived endothelium-derived hyperpolarizing factor in essential hypertensive patients. *J Am Coll Cardiol*. 2006;48:508–515.

39. Minuz P, Jiang H, Fava C, Turolo L, Tacconelli S, Ricci M, Patrignani P, Morganti A, Lechi A, McGiff JC. Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. *Hypertens Dallas Tex 1979*. 2008;51:1379–1385.

40. Watanabe H, Katoh T, Eiro M, Iwamoto M, Ushikubi F, Narumiya S, Watanabe T. Effects of salt loading on blood pressure in mice lacking the prostanoid receptor gene. *Circ J Off J Jpn Circ Soc*. 2005;69:124–126.

41. Yu Y, Stubbe J, Ibrahim S, Song W, Symth EM, Funk CD, FitzGerald GA. COX-2 Dependent Prostacyclin Formation and Blood Pressure Homeostasis: Targeted Exchange of COX Isoforms in Mice. *Circ Res*. 2010;106:337.

42. Snowden S, Nelson R. The effects of nonsteroidal anti-inflammatory drugs on blood pressure in hypertensive patients. *Cardiol Rev*. 2011;19:184–191.

43. DeFilippis AP, Oloyede OS, Andrikopoulou E, Saenger AK, Palachuvattil JM, Fasoro YA, Guallar E, Blumenthal RS, Kickler TS, Jaffe AS, Gerstenblith G,

Schulman SP, Rade JJ. Thromboxane A(2) generation, in the absence of platelet COX-1 activity, in patients with and without atherothrombotic myocardial infarction. *Circ J Off J Jpn Circ Soc*. 2013;77:2786–2792.

44. Eikelboom JW, Hankey GJ, Thom J, Bhatt DL, Steg PG, Montalescot G, Johnston SC, Steinhubl SR, Mak K-H, Easton JD, Hamm C, Hu T, Fox KAA, Topol EJ, Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Investigators. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. *Circulation*. 2008;118:1705–1712.

45. Fitzgerald DJ, Rocki W, Murray R, Mayo G, FitzGerald GA. Thromboxane A2 synthesis in pregnancy-induced hypertension. *Lancet Lond Engl*. 1990;335:751–754.

46. Mezei Z, Kis B, Gecse Á, Telegdy G, Ábrahám G, Sonkodi S. Platelet eicosanoids and the effect of captopril in blood pressure regulation. *Eur J Pharmacol*. 1997;340:67–73.

47. Maddipati KR, Romero R, Chaiworapongsa T, Zhou S-L, Xu Z, Tarca AL, Kusanovic JP, Munoz H, Honn KV. Eicosanomic profiling reveals dominance of the epoxygenase pathway in human amniotic fluid at term in spontaneous labor. *FASEB J*. 2014;28:4835–4846.

48. Kopf PG, Zhang DX, Gauthier KM, Nithipatikom K, Yi X-Y, Falck JR, Campbell WB. Adrenic acid metabolites as endogenous endothelium-derived and zona

glomerulosa-derived hyperpolarizing factors. *Hypertens Dallas Tex 1979*. 2010;55:547–554.

Figure Legends

Figure 1. Manhattan plot for associations between eicosanoids and systolic blood pressure in FINRISK 2002.

Figure 2. Correlation matrix for the 187 plasma eicosanoids related to systolic blood pressure in FINRISK 2002.

Figure 3. The associations between the six eicosanoids independently related to systolic BP in FINRISK and replication results in FHS.

Figure 4. The association between a 6-eicosanoid risk score and systolic blood pressure in FINRISK and FHS.

Figure 5. The association between a 6-eicosanoid risk score and hypertension in FINRISK and FHS.

Novelty and Significance

- **What is New**
    - Fatty acid-derived eicosanoids serve as mediators of inflammation and have been suggested to regulate renal vascular tone, peripheral resistance, renin-angiotensin system, and endothelial function.
    - We assayed a comprehensive panel of >500 distinct high-quality eicosanoids and related oxylipin mediators in community-based samples of >10 000 individuals using liquid chromatography-mass spectrometry and relate these eicosanoids and eicosanoid profiles to blood pressure traits.

- **What is relevant**
    - We observed that 187 (34%) eicosanoids and related oxylipin mediators were significantly associated with systolic blood pressure.
    - Individuals in the top quartile of a six-metabolite risk score had a 9.0 mmHg higher systolic blood pressure and 2-fold greater odds of hypertension compared to individuals in the bottom quartile.

Summary

As eicosanoid species affect numerous physiological processes that are central to BP regulation, they may offer new insights regarding pathogenesis of hypertension, as well as serve as potential new targets for therapeutic intervention.

Tables

Table 1. Characteristics of the discovery (FINRISK) and replication (FHS) samples.

Characteristics	FINRISK 2002	FHS
N	8099	2859
Age, y (SD)	48.0 (13.1)	66.3 (8.9)
Women, N (%)	4300 (53.1)	1564 (54.7)
BMI, kg/m² (SD)	26.9 (4.7)	28.3 (5.4)
Systolic blood pressure, mmHg (SD)	135.1 (20.0)	128.5 (17.2)
Diastolic blood pressure, mmHg (SD)	79.0 (11.3)	73.4 (10.1)
Pulse pressure, mmHg (SD)	56.1 (16.1)	55.1 (16.0)
Mean arterial pressure, mmHg (SD)	97.7 (12.7)	91.8 (10.5)
Hypertension, N (%)	3567 (44.0)	1673 (58.5)
Antihypertensive medication, N (%)	1177 (14.5)	1389 (48.6)
Current smoker, N (%)	2097 (25.9)	256 (9.0)
Diabetes mellitus, N (%)	446 (5.5)	393 (13.7)

Continuous variables are presented as mean (standard deviation). Categorical variables reported as absolute and relative frequencies. BMI, body mass index; FHS, Framingham Heart Study.

Figure 1. Manhattan plot for associations between metabolites and systolic blood pressure in FINRISK 2002.



A significant association was observed for 187 of the 545 eicosanoids. Positive correlations are denoted in red, negative in blue and insignificant in gray. Eicosanoids are ordered by the value of mass to charge ratio (m/z). Dashed line represents the Bonferroni corrected (p=0.05/545) level of significance. Analyses are adjusted for age, sex, BMI, current smoking, diabetes, antihypertensive medication, and batch.

Figure 2. Correlation matrix for the 187 plasma metabolites related to systolic blood pressure in FINRISK 2002.



Relations between eicosanoids were calculated using Spearman correlation and ordered using hierarchical cluster analysis with complete linkage method. Only eicosanoids related to systolic blood pressure were included in the correlation matrix. Asterisk denotes position of the six metabolites in our eicosanoid risk score (**Figure 3**).

Figure 3. The associations between a subset of six metabolites and systolic BP in FINRISK and replication of results in FHS.



The beta coefficients are for the association between 1-SD increase in metabolite concentration and the absolute change of systolic blood pressure (mmHg) in the two study cohorts. All models were adjusted for age, sex, BMI, current smoking, diabetes, antihypertensive medication, and batch. Two of the six eicosanoids observed in FINRISK were not observed in FHS plasma samples. FHS, Framingham Heart Study; HHTrE, hydroxyheptadecatrenoic acid; TXB2, thromboxane B2; HETE, hexadecatrienoic acid.

Figure 4. The association between the risk score and systolic blood pressure in FINRISK and FHS.



We calculated eicosanoid risk score for each participant according to the formula $\beta_1X_1 + \beta_2X_2 + ... + \beta_nX_n$, with X_n denoting the standardized value for the nth eicosanoid abundance, and β_n denoting the regression coefficient from the regression model containing the indicated eicosanoids. Analyses are adjusted for age, sex, BMI, current smoking, diabetes and antihypertensive medication and batch. FHS, Framingham Heart Study; BP, blood pressure.

Figure 5. The association between the risk score and hypertension in FINRISK and FHS.



We calculated eicosanoid risk score for each participant according to the formula $\beta_1X_1 + \beta_2X_2 + ... + \beta_nX_n$ with X_n denoting the standardized value for the nth eicosanoid abundance, and β_n denoting the regression coefficient from the regression model in FINRISK containing the indicated eicosanoids. Multivariable analyses are adjusted for age, sex, BMI, current smoking, diabetes and antihypertensive medication and batch. FHS, Framingham Heart Study; BP, blood pressure.